Wall Street analysts forecast that Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will report earnings per share (EPS) of $2.67 for the current quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Regeneron Pharmaceuticals’ earnings. Regeneron Pharmaceuticals reported earnings per share of $2.11 in the same quarter last year, which suggests a positive year over year growth rate of 26.5%. The business is expected to issue its next earnings results on Thursday, August 3rd.

On average, analysts expect that Regeneron Pharmaceuticals will report full year earnings of $10.52 per share for the current fiscal year, with EPS estimates ranging from $10.33 to $10.71. For the next financial year, analysts anticipate that the business will post earnings of $12.10 per share, with EPS estimates ranging from $11.57 to $12.62. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.42. Regeneron Pharmaceuticals had a net margin of 19.34% and a return on equity of 22.99%. The business had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.30 billion. During the same period last year, the business earned $2.57 earnings per share. The firm’s revenue was up 9.8% on a year-over-year basis.

A number of research analysts have issued reports on REGN shares. Sanford C. Bernstein restated an “outperform” rating on shares of Regeneron Pharmaceuticals in a research note on Thursday, May 25th. Canaccord Genuity restated a “hold” rating and issued a $375.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, March 30th. Oppenheimer Holdings, Inc. started coverage on Regeneron Pharmaceuticals in a research note on Thursday, March 16th. They issued a “hold” rating for the company. BMO Capital Markets restated a “hold” rating and issued a $412.00 price objective (up previously from $408.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 28th. Finally, Leerink Swann restated an “outperform” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, March 20th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have issued a buy rating to the stock. Regeneron Pharmaceuticals has an average rating of “Hold” and an average price target of $434.17.

Shares of Regeneron Pharmaceuticals (REGN) traded down 2.04% during midday trading on Wednesday, reaching $459.91. The company’s stock had a trading volume of 1,658,740 shares. Regeneron Pharmaceuticals has a one year low of $325.35 and a one year high of $489.00. The firm has a 50-day moving average of $450.98 and a 200-day moving average of $392.16. The stock has a market cap of $48.55 billion, a PE ratio of 55.67 and a beta of 1.53. Regeneron Pharmaceuticals also was the recipient of some unusual options trading on Wednesday. Investors purchased 1,049 call options on the company. This represents an increase of approximately 368% compared to the average daily volume of 224 call options.

COPYRIGHT VIOLATION WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) Expected to Announce Earnings of $2.67 Per Share” was reported by Financial Market News and is the property of of Financial Market News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.financial-market-news.com/2017/06/17/regeneron-pharmaceuticals-inc-regn-expected-to-announce-earnings-of-2-67-per-share.html.

In other Regeneron Pharmaceuticals news, major shareholder Sanofi purchased 136,050 shares of the stock in a transaction on Friday, June 2nd. The shares were purchased at an average price of $478.17 per share, with a total value of $65,055,028.50. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Michael S. Brown sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, March 29th. The shares were sold at an average price of $400.00, for a total value of $400,000.00. Following the completion of the sale, the director now directly owns 1,000 shares in the company, valued at approximately $400,000. The disclosure for this sale can be found here. In the last ninety days, insiders sold 25,674 shares of company stock worth $11,852,498. Insiders own 10.40% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the stock. Prudential PLC acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $11,267,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in Regeneron Pharmaceuticals by 0.6% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 4,334 shares of the biopharmaceutical company’s stock valued at $1,591,000 after buying an additional 24 shares during the last quarter. Baird Financial Group Inc. boosted its stake in Regeneron Pharmaceuticals by 1.3% in the fourth quarter. Baird Financial Group Inc. now owns 17,144 shares of the biopharmaceutical company’s stock valued at $6,293,000 after buying an additional 221 shares during the last quarter. Federated Investors Inc. PA boosted its stake in Regeneron Pharmaceuticals by 4,748.3% in the fourth quarter. Federated Investors Inc. PA now owns 154,371 shares of the biopharmaceutical company’s stock valued at $56,668,000 after buying an additional 151,187 shares during the last quarter. Finally, FIL Ltd boosted its stake in Regeneron Pharmaceuticals by 4.9% in the fourth quarter. FIL Ltd now owns 35,840 shares of the biopharmaceutical company’s stock valued at $13,157,000 after buying an additional 1,689 shares during the last quarter. 67.25% of the stock is currently owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.